Pharming Group (NASDAQ:PHAR) Sees Unusually-High Trading Volume

Shares of Pharming Group (NASDAQ:PHARGet Free Report) saw unusually-strong trading volume on Friday . Approximately 1,585 shares traded hands during mid-day trading, a decline of 53% from the previous session’s volume of 3,340 shares.The stock last traded at $8.59 and had previously closed at $8.73.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a report on Friday, May 31st.

Read Our Latest Analysis on Pharming Group

Pharming Group Trading Down 1.6 %

The stock’s fifty day moving average is $9.76 and its two-hundred day moving average is $11.01.

Pharming Group (NASDAQ:PHARGet Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.20). The business had revenue of $55.59 million for the quarter, compared to the consensus estimate of $68.43 million. Pharming Group had a negative return on equity of 4.61% and a negative net margin of 4.01%. On average, equities research analysts predict that Pharming Group will post -0.03 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently bought a new position in Pharming Group stock. Silverberg Bernstein Capital Management LLC acquired a new position in Pharming Group (NASDAQ:PHARFree Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 17,710 shares of the company’s stock, valued at approximately $202,000. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

(Get Free Report)

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

See Also

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with's FREE daily email newsletter.